Systemic lupus erythematosus (SLE) is a genetically predisposed, female-predominant disease, characterized by multiple organ damage, that in its most severe forms can be life-threatening. The pathogenesis of SLE is complex and involves cells of both innate and adaptive immunity. The distinguishing feature of SLE is the production of autoantibodies, with the formation of immune complexes that precipitate at the vascular level, causing organ damage. Although progress in understanding the pathogenesis of SLE has been slower than in other rheumatic diseases, new knowledge has recently led to the development of effective targeted therapies, that hold out hope for personalized therapy. However, the new drugs available to date are still an adjunct to conventional therapy, which is known to be toxic in the short and long term. The purpose of this review is to summarize recent advances in understanding the pathogenesis of the disease and discuss the results obtained from the use of new targeted drugs, with a look at future therapies that may be used in the absence of the current standard of care or may even cure this serious systemic autoimmune disease.

Advances in the pathogenesis and treatment of systemic lupus erythematosus / Accapezzato, D.; Caccavale, R.; Paroli, M. P.; Gioia, C.; Nguyen, B. L.; Spadea, L.; Paroli, M.. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - 24:7(2023). [10.3390/ijms24076578]

Advances in the pathogenesis and treatment of systemic lupus erythematosus

Accapezzato D.
Primo
;
Caccavale R.
Secondo
;
Paroli M. P.;Gioia C.;Nguyen B. L.;Spadea L.
Penultimo
;
Paroli M.
Ultimo
2023

Abstract

Systemic lupus erythematosus (SLE) is a genetically predisposed, female-predominant disease, characterized by multiple organ damage, that in its most severe forms can be life-threatening. The pathogenesis of SLE is complex and involves cells of both innate and adaptive immunity. The distinguishing feature of SLE is the production of autoantibodies, with the formation of immune complexes that precipitate at the vascular level, causing organ damage. Although progress in understanding the pathogenesis of SLE has been slower than in other rheumatic diseases, new knowledge has recently led to the development of effective targeted therapies, that hold out hope for personalized therapy. However, the new drugs available to date are still an adjunct to conventional therapy, which is known to be toxic in the short and long term. The purpose of this review is to summarize recent advances in understanding the pathogenesis of the disease and discuss the results obtained from the use of new targeted drugs, with a look at future therapies that may be used in the absence of the current standard of care or may even cure this serious systemic autoimmune disease.
2023
B-cells; T-cells; cell-based therapy; plasmacytoid cells; systemic lupus erythematosus; type-I interferon
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Advances in the pathogenesis and treatment of systemic lupus erythematosus / Accapezzato, D.; Caccavale, R.; Paroli, M. P.; Gioia, C.; Nguyen, B. L.; Spadea, L.; Paroli, M.. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - 24:7(2023). [10.3390/ijms24076578]
File allegati a questo prodotto
File Dimensione Formato  
Accapezzato_Advances in_2023.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 869.75 kB
Formato Adobe PDF
869.75 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1678197
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 5
social impact